| ALTIMMUNE INC. DL-,0001 |
| USA |
| Gesundheit |
| US02155H2004 / A2N5Z6 |
| 3G0 (Frankfurt) / ALT (NASDAQ) |
| FRA:3G0, ETR:3G0, 3G0:GR, NASDAQ:ALT |
| - |
| https://altimmune.com/ |
|
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucago..
>Volltext.. |
| 340.19 Mio. EUR |
| 84.44 Mio. EUR |
| 0.03 Mio. EUR |
| -89.54 Mio. EUR |
| -82.72 Mio. EUR |
| -0.71 EUR |
| 32.47 Mio. EUR |
| 56.84 Mio. EUR |
| -68.7 Mio. EUR |
| 26.1 |
| 59.88% |
| -7.86% |
| - |
| - |
| - |
| 20.01.17 - 224502.93€ |
| - |
| ALTIMMUNE |
| 12.11.26 |
|
||||
|
||||
|
||||
|